270 related articles for article (PubMed ID: 17343369)
1. Ovarian cancer activity of cyclic amine and thiaether metal complexes.
Medvetz DA; Stakleff KD; Schreiber T; Custer PD; Hindi K; Panzner MJ; Blanco DD; Taschner MJ; Tessier CA; Youngs WJ
J Med Chem; 2007 Apr; 50(7):1703-6. PubMed ID: 17343369
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.
Marzano C; Pellei M; Colavito D; Alidori S; Lobbia GG; Gandin V; Tisato F; Santini C
J Med Chem; 2006 Dec; 49(25):7317-24. PubMed ID: 17149861
[TBL] [Abstract][Full Text] [Related]
3. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral activity of non-platinum xanthate complexes.
Friebolin W; Schilling G; Zöller M; Amtmann E
J Med Chem; 2005 Dec; 48(25):7925-31. PubMed ID: 16335917
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.
Herman A; Tanski JM; Tibbetts MF; Anderson CM
Inorg Chem; 2008 Jan; 47(1):274-80. PubMed ID: 18062685
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells.
Barve V; Ahmed F; Adsule S; Banerjee S; Kulkarni S; Katiyar P; Anson CE; Powell AK; Padhye S; Sarkar FH
J Med Chem; 2006 Jun; 49(13):3800-8. PubMed ID: 16789737
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
9. DNA binding studies of novel Copper(II) complexes containing L-tryptophan as chiral auxiliary: in vitro antitumor activity of Cu-Sn2 complex in human neuroblastoma cells.
Chauhan M; Banerjee K; Arjmand F
Inorg Chem; 2007 Apr; 46(8):3072-82. PubMed ID: 17378549
[TBL] [Abstract][Full Text] [Related]
10. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
11. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structure and antitumor activity of [RhCl3(N-N)(DMSO)] polypyridyl complexes.
Sliwińska U; Pruchnik FP; Pelińska I; Ułaszewski S; Wilczok A; Zajdel A
J Inorg Biochem; 2008 Oct; 102(10):1947-51. PubMed ID: 18718669
[TBL] [Abstract][Full Text] [Related]
13. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
15. Thioamido coordination in a thioxo-1,2,4-triazole copper(II) complex enhances nonapoptotic programmed cell death associated with copper accumulation and oxidative stress in human cancer cells.
Tardito S; Bussolati O; Maffini M; Tegoni M; Giannetto M; Dall'asta V; Franchi-Gazzola R; Lanfranchi M; Pellinghelli MA; Mucchino C; Mori G; Marchio L
J Med Chem; 2007 Apr; 50(8):1916-24. PubMed ID: 17373781
[TBL] [Abstract][Full Text] [Related]
16. New approach for the preparation of efficient DNA cleaving agents: ditopic copper-platinum complexes based on 3-Clip-Phen and cisplatin.
Hoog Pd; Boldron C; Gamez P; Sliedregt-Bol K; Roland I; Pitié M; Kiss R; Meunier B; Reedijk J
J Med Chem; 2007 Jun; 50(13):3148-52. PubMed ID: 17521178
[TBL] [Abstract][Full Text] [Related]
17. 3,5-Dimethyl-1-thiocarbamoylpyrazole and its Pd(II) complexes: synthesis, spectral studies and antitumor activity.
Rocha FV; Barra CV; Netto AV; Mauro AE; Carlos IZ; Frem RC; Ananias SR; Quilles MB; Stevanato A; da Rocha MC
Eur J Med Chem; 2010 May; 45(5):1698-702. PubMed ID: 20116142
[TBL] [Abstract][Full Text] [Related]
18. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
19. Metal-NHC complexes: a survey of anti-cancer properties.
Teyssot ML; Jarrousse AS; Manin M; Chevry A; Roche S; Norre F; Beaudoin C; Morel L; Boyer D; Mahiou R; Gautier A
Dalton Trans; 2009 Sep; (35):6894-902. PubMed ID: 20449127
[TBL] [Abstract][Full Text] [Related]
20. Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride.
Waern JB; Dillon CT; Harding MM
J Med Chem; 2005 Mar; 48(6):2093-9. PubMed ID: 15771451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
